Tougher induction chemo for CLL better for later quality of life


According to findings published in Leukemia & Lymphoma, patients diagnosed with chronic lymphocytic leukemia (CLL) can achieve a good quality of life after they have fully completed treatment. This is important because CLL affects elderly patients chiefly, meaning that side effects and toxicity can have especially damaging effects.

The findings come from a trial of 777 CLL patients tracked for five years. Patients received either:

-- Fludarabine
-- Chlorambucil
-- Fludarabine and cyclophosphamide (FC)

Currently, fludarabine and cyclophosphamide plus Rituxan is considered the standard of care in this patient population, but concerns over difficult to manage side effects has had an impact on quality of life.

What researchers learned is that while FC therapy was indeed more harsh, this only remained true during treatment. Over the long run, patients receiving this treatment reported the same measures of quality of life as people of the same age and sex without cancer.

Source: Medical News Today

LymphomaInfo Social